about
Ethnicity and prostate cancer: the way to solve the screening problem?Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review.Active surveillance for prostate cancer: a narrative review of clinical guidelines.Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.How Often is Biopsy Necessary in Patients with Prostate Cancer on Active Surveillance?[Guidelines on the early detection of prostate cancer]Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC RotterdamDo Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?The ProtecT trial: what can we expect?
P50
Q35736485-11E5D272-492A-4B9D-B583-11F5D548E0D1Q38289798-57CCF5A2-C8B1-4FBC-BEC6-D1356BF8E7DDQ38712706-B38949DA-E3F9-4322-9F26-FE46CFD2E6FBQ38764526-F91E2F0F-912A-41B4-8480-32927A89A6EFQ38924660-8B0B6633-8334-4C62-9A59-1B1E5142B5FAQ40109539-3B3F4652-AE7D-4D15-B112-36662EA6FCA5Q40227639-01EF9CBF-37D0-4832-AC73-F7546D68641FQ40293482-A7A08E32-339D-439D-99A0-70B690B0F658Q40383850-EC22C430-33DA-41B9-878F-C68CD9C06612Q41599088-76BF9CED-0803-4C04-A70E-6561211FBCC4Q42287916-536AFBEF-E476-4BEA-8FEB-1F6B285D6924Q42708785-F840F47C-48A6-4D46-A84B-8C97FF944AF5Q46540196-319EC57E-1DFB-46CC-BA25-C0CBDC1F22D1Q48701068-78B1263F-21E4-4867-978C-2AB6B3D7DC82Q51312747-ADCE2DDD-D7F9-434F-B5E7-26D9A3F6BEC8Q53308307-A8389867-BE4E-4207-8BDE-D98FFFC7E977Q57125552-16824E00-5D6A-4F34-BEA6-F4C305854D39Q86132968-CD366018-DDF2-4062-972D-8E134C5F6E38Q86778752-93A213BE-1283-4EE3-8BAF-A313B7669ECCQ87673915-3A98EACF-D0DE-4C3D-A618-B935E03E61B9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Leonard P Bokhorst
@ast
Leonard P Bokhorst
@en
Leonard P Bokhorst
@es
Leonard P Bokhorst
@nl
type
label
Leonard P Bokhorst
@ast
Leonard P Bokhorst
@en
Leonard P Bokhorst
@es
Leonard P Bokhorst
@nl
prefLabel
Leonard P Bokhorst
@ast
Leonard P Bokhorst
@en
Leonard P Bokhorst
@es
Leonard P Bokhorst
@nl
P106
P21
P31
P496
0000-0003-1154-4794